As of Friday close, Terns Pharmaceuticals Inc.’s (NASDAQ:TERN) stock was down -$0.14, moving down -2.64 percent to $5.17. The average number of shares traded per day over the past five days has been 764,160 shares. 3 times new highs have been achieved over the past 5 days, with a $0.05 gain in that time frame. In the last twenty days, the average volume was 461,850, while in the previous 50 days, it was 606,352.
Since last month, TERN stock retreated -6.00%. Shares of the company fell to $4.95 on 09/21/23, the lowest level in the past month. A 52-week high of $14.04 was reached on 04/20/23 after having rallying from a 52-week low of $4.38. Since the beginning of this year, TERN’s stock price has dropped by -49.21% or -$5.01, and marked a new high 8 times. However, the stock has declined by -63.19% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
TERN stock investors should be aware that Terns Pharmaceuticals Inc. (TERN) stock had its last reported insider trading activity 274 days ago on Dec 23. Lu Hongbo, the Director of the company, purchased of 758,620 shares for $7.25 on Dec 23. It resulted in a $5,499,995 investment by the insider. Vivo Opportunity, LLC added 758,620 shares at an average price of $7.25 on Dec 23. The insider now owns 4,340,212 shares following the transaction. On Dec 23, Director ORBIMED ADVISORS LLC bought 137,931 shares at $7.25 apiece. The transaction was valued at $1,000,000.
Financial Health
In the three months ended June 30, Terns Pharmaceuticals Inc.’s quick ratio stood at 20.20, while its current ratio was 20.20, showing that the company is able to pay off its debt. Based on annual data, TERN earned $62.03 million in gross profit.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Terns Pharmaceuticals Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.25 per share, beating the consensus estimate by 26.50%. During the quarter, the company generated -$21.92 million in EBITDA. The liabilities of Terns Pharmaceuticals Inc. were 15.55 million at the end of its most recent quarter ended June 30, and its total debt was $0.88 million. The value of shareholders’ equity is $61.07 million.
Technical Picture
This quick technical analysis looks at Terns Pharmaceuticals Inc.’s (TERN) price momentum. With a historical volatility rate of 37.10%, the RSI 9-day stood at 41.98% on 22 September.
With respect to its five-day moving average, the current Terns Pharmaceuticals Inc. price is up by +0.98% percent or $0.05. At present, TERN shares trade -7.18% below its 20-day simple moving average and -60.02% percent below its 100-day simple moving average. However, the stock is currently trading approximately -36.80% below its SMA50 and -15.11% below its SMA200.
Stochastic coefficient K was 34.58% and Stochastic coefficient D was 35.32%, while ATR was 0.30. Given the Stochastic reading of 31.43% for the 14-day period, the RSI (14) reading has been calculated as 39.35%.
Analyst Ratings
Mizuho launched its rating on Terns Pharmaceuticals Inc. (NASDAQ: TERN) to a Buy in a note to investors on June 22, 2023. Terns Pharmaceuticals Inc. (TERN) has been rated Buy by analysts. According to 0 brokerage firms, TERN is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Terns Pharmaceuticals Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $17.50, the current consensus forecast for the stock is $8.00 – $25.00. Based on these forecasts, analysts predict Terns Pharmaceuticals Inc. (TERN) will achieve an average price target of $16.63.
